| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H36Cl2N8O5 |
| Molecular Weight | 815.703 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CNC2=C(O)C=C3N(C[C@@H](CCl)C3=C12)C(=O)C4=CC5=C(N4)C=CC(NC(=O)NC6=CC7=C(NC(=C7)C(=O)N8C[C@@H](CCl)C9=C%10C(C)=CNC%10=C(O)C=C89)C=C6)=C5
InChI
InChIKey=FONKWHRXTPJODV-DNQXCXABSA-N
InChI=1S/C43H36Cl2N8O5/c1-19-15-46-39-33(54)11-31-37(35(19)39)23(13-44)17-52(31)41(56)29-9-21-7-25(3-5-27(21)50-29)48-43(58)49-26-4-6-28-22(8-26)10-30(51-28)42(57)53-18-24(14-45)38-32(53)12-34(55)40-36(38)20(2)16-47-40/h3-12,15-16,23-24,46-47,50-51,54-55H,13-14,17-18H2,1-2H3,(H2,48,49,58)/t23-,24-/m1/s1
| Molecular Formula | C43H36Cl2N8O5 |
| Molecular Weight | 815.703 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bizelesin (previously known as U-77779 or NSC 615291), a cyclopropylpyrroloindole antitumor agent acts as a bifunctional alkylating agent and produces DNA interstrand cross-links. This drug participated in phase I clinical trials in patients with advanced solid malignancies, however further development was discontinued.
Originator
Approval Year
PubMed
Sample Use Guides
Patients with advanced solid malignancies were treated with escalating doses of bizelesin as an i.v. bolus injection every 4 weeks. The selection of the specific starting dose, 0.1 micro g/m(2), which was equivalent to one-tenth the toxic dose low in dogs, factored in large interspecies differences in myelotoxicity as gauged using an ex vivo hematopoietic colony-forming assay
Route of Administration:
Intravenous
